Go to
JCI Insight
Citations to this article
Okechi S. Oduori, … , Patrik Rorsman, Susumu Seino
Published November 16, 2020
Citation Information: J Clin Invest. 2020;130(12):6639-6655. https://doi.org/10.1172/JCI140046.
Citation Information: J Clin Invest. 2020;130(12):6639-6655. https://doi.org/10.1172/JCI140046.
Abstract
By restoring glucose-regulated insulin secretion, glucagon-like peptide-1–based (GLP-1–based) therapies are becoming increasingly important in diabetes care. Normally, the incretins GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) jointly maintain normal blood glucose levels by stimulation of insulin secretion in pancreatic β cells. However, the reason why only GLP-1–based drugs are effective in improving insulin secretion after presentation of diabetes has not been resolved. ATP-sensitive K+ (KATP) channels play a crucial role in coupling the systemic metabolic status to β cell electrical activity for insulin secretion. Here, we have shown that persistent membrane depolarization of β cells due to genetic (β cell–specific Kcnj11–/– mice) or pharmacological (long-term exposure to sulfonylureas) inhibition of the KATP channel led to a switch from Gs to Gq in a major amplifying pathway of insulin secretion. The switch determined the relative insulinotropic effectiveness of GLP-1 and GIP, as GLP-1 can activate both Gq and Gs, while GIP only activates Gs. The findings were corroborated in other models of persistent depolarization: a spontaneous diabetic KK-Ay mouse and nondiabetic human and mouse β cells of pancreatic islets chronically treated with high glucose. Thus, a Gs/Gq signaling switch in β cells exposed to chronic hyperglycemia underlies the differential insulinotropic potential of incretins in diabetes.
Authors
Okechi S. Oduori, Naoya Murao, Kenju Shimomura, Harumi Takahashi, Quan Zhang, Haiqiang Dou, Shihomi Sakai, Kohtaro Minami, Belen Chanclon, Claudia Guida, Lakshmi Kothegala, Johan Tolö, Yuko Maejima, Norihide Yokoi, Yasuhiro Minami, Takashi Miki, Patrik Rorsman, Susumu Seino
Citation information
Citations to this article (46)
| Title and authors | Publication | Year |
|---|---|---|
|
Commonalities and differences in the mechanism of GLP-1 and insulin secretion highlight Gs-targeting diabetes treatment
Junichiro SATO, Katsunori MANAKA, Hirofumi HORIKOSHI, Maho TAGUCHI, Kazuki HARADA, Takashi TSUBOI, Masaomi NANGAKU, Taroh IIRI, Noriko MAKITA |
Scientific reports | 2025 |
|
Binding Kinetics, Bias, Receptor Internalization and Effects on Insulin Secretion in vitro and in vivo of a Novel GLP-1R/GIPR Dual Agonist, HISHS-2001
Manchanda Y, Jones B, Carrat G, Ramchunder Z, Marchetti P, Leclerc I, Thennati R, Burade V, Natarajan M, Shahi P, Tomas A, Rutter GA |
bioRxiv | 2025 |
|
Glucose-dependent insulinotropic polypeptide (GIP)
Müller TD, Adriaenssens A, Ahrén B, Blüher M, Birkenfeld AL, Campbell JE, Coghlan MP, D'Alessio D, Deacon CF, DelPrato S, Douros JD, Drucker DJ, Figueredo Burgos NS, Flatt PR, Finan B, Gimeno RE, Gribble FM, Hayes MR, Hölscher C, Holst JJ, Knerr PJ, Knop FK, Kusminski CM, Liskiewicz A, Mabilleau G, Mowery SA, Nauck MA, Novikoff A, Reimann F, Roberts AG, Rosenkilde MM, Samms RJ, Scherer PE, Seeley RJ, Sloop KW, Wolfrum C, Wootten D, DiMarchi RD, Tschöp MH |
Molecular Metabolism | 2025 |
|
Pyruvate kinase modulates the link between β‐cell fructose metabolism and insulin secretion
Murao N, Morikawa R, Seino Y, Shimomura K, Maejima Y, Ohno T, Yokoi N, Yamada Y, Suzuki A |
The FASEB Journal | 2025 |
|
The C-terminal regions of the GLP-1 and GIP receptors are not the key determinants of their differential arrestin recruitment but modulate the rate of receptor endocytosis
Al-Zaid B, Al-Sabah S |
Frontiers in Pharmacology | 2025 |
|
β‐Adrenergic Blockers Increase cAMP and Stimulate Insulin Secretion Through a PKA/RYR2/TRPM5 Pathway in Pancreatic β‐Cells In Vitro
Murao N, Morikawa R, Seino Y, Shimomura K, Maejima Y, Yamada Y, Suzuki A |
Pharmacology Research & Perspectives | 2025 |
|
Molecular mechanism responsible for sex differences in pancreatic β-cell insulin release
Noelia Jacobo-Piqueras, Tamara Theiner, Stefanie M. Geisler, Petronel Tuluc |
JCI Insight | 2024 |
|
The GLP-1 journey: from discovery science to therapeutic impact.
Drucker DJ |
Journal of Clinical Investigation | 2024 |
|
Beta-Cell Tipe1 Orchestrates Insulin Secretion and Cell Proliferation by Promoting Gαs/cAMP Signaling via USP5.
Ding L, Sun Y, Liang Y, Zhang J, Fu Z, Ren C, Li P, Liu W, Xiao R, Wang H, Zhang Z, Yue X, Li C, Wu Z, Feng Y, Liang X, Ma C, Gao L |
2024 | |
|
Sildenafil amplifies calcium influx and insulin secretion in pancreatic β cells
Murao N, Morikawa R, Seino Y, Shimomura K, Maejima Y, Yamada Y, Suzuki A |
Physiological Reports | 2024 |
|
G Protein-Coupled Receptors: A Century of Research and Discovery
Liu S, Anderson PJ, Rajagopal S, Lefkowitz RJ, Rockman HA |
Circulation research | 2024 |
|
Disrupted Endoplasmic Reticulum Ca2+ Handling: A Harβinger of β-Cell Failure
Dobson JR, Jacobson DA |
Biology | 2024 |
|
Ca2+ signaling and metabolic stress-induced pancreatic β-cell failure
Magnuson MA, Osipovich AB |
Frontiers in Endocrinology | 2024 |
|
Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
Liu QK |
Frontiers in Endocrinology | 2024 |
|
Pharmacological Advances in Incretin-Based Polyagonism: What We Know and What We Don’t
Novikoff A, Müller TD |
Physiology | 2024 |
|
Tirzepatide, GIP(1-42) and GIP(1-30) display unique signaling profiles at two common GIP receptor variants, E354 and Q354.
Rees TA, Buttle BJ, Tasma Z, Yang SH, Harris PWR, Walker CS |
Frontiers in pharmacology | 2024 |
|
Differential effects of imeglimin and metformin on insulin and incretin secretion—An exploratory randomized controlled trial
Usui R, Hamamoto Y, Imura M, Omori Y, Yamazaki Y, Kuwata H, Tatsuoka H, Shimomura K, Murotani K, Yamada Y, Seino Y |
Diabetes, Obesity & Metabolism | 2024 |
|
Incretin hormones and Obesity
Alcaino C, Reimann F, Gribble FM |
The Journal of physiology | 2024 |
|
Loss of β-Cell KATP Reduces Ca2+ Sensitivity of Insulin Secretion and Trpm5 Expression
York NW, Yan Z, Osipovich AB, Tate A, Patel S, Piston DW, Magnuson MA, Remedi MS, Nichols CG |
Diabetes | 2024 |
|
GLP-1R Signaling and Functional Molecules in Incretin Therapy
Wan W, Qin Q, Xie L, Zhang H, Wu F, Stevens RC, Liu Y |
Molecules (Basel, Switzerland) | 2023 |
|
Enhanced Endosomal Signaling and Desensitization of GLP-1R vs GIPR in Pancreatic Beta Cells
Manchanda Y, Bitsi S, Chen S, Broichhagen J, Bernardino de la Serna J, Jones B, Tomas A |
Endocrinology | 2023 |
|
The expanding incretin universe: from basic biology to clinical translation.
Drucker DJ, Holst JJ |
Diabetologia | 2023 |
|
RISING STARS: Targeting G protein-coupled receptors to regulate energy homeostasis.
Jamaluddin A, Gorvin CM |
Journal of molecular endocrinology | 2023 |
|
Glucose-stimulated insulin secretion depends on FFA1 and Gq in neonatal mouse islets.
Lorza-Gil E, Kaiser G, Carlein C, Hoffmann MDA, König GM, Haug S, Prates Roma L, Rexen Ulven E, Ulven T, Kostenis E, Birkenfeld AL, Häring HU, Ullrich S, Gerst F |
Diabetologia | 2023 |
|
Stimulatory effect of imeglimin on incretin secretion
Yingyue Q, Sugawara K, Takahashi H, Yokoi N, Ohbayashi K, Iwasaki Y, Seino S, Ogawa W |
Journal of Diabetes Investigation | 2023 |
|
Incretin hormones and type 2 diabetes.
Nauck MA, Müller TD |
Diabetologia | 2023 |
|
ER stress and unfolded protein response (UPR) signaling modulate GLP-1 receptor signaling in the pancreatic islets
Gao Y, Ryu H, Lee H, Kim YJ, Lee JH, Lee J |
Molecules and Cells | 2023 |
|
Increased glycolysis affects β-cell function and identity in aging and diabetes
N Murao, N Yokoi, H Takahashi, T Hayami, Y Minami, S Seino |
Molecular Metabolism | 2022 |
|
Effects of Arachidonic Acid and Its Metabolites on Functional Beta-Cell Mass
K Bosma, C Kaiser, M Kimple, M Gannon |
Metabolites | 2022 |
|
ATP-Sensitive Potassium Channels in Hyperinsulinism and Type 2 Diabetes: Inconvenient Paradox or New Paradigm?
C Nichols, N York, M Remedi |
Diabetes | 2022 |
|
Differential effects of glucose‐dependent insulinotropic polypeptide receptor/glucagon‐like peptide‐1 receptor heteromerization on cell signaling when expressed in HEK‐293 cells
Al\u2010Zaid B, Chacko S, Ezeamuzie CI, Bünemann M, Krasel C, Karimian T, Lanzerstorfer P, Al\u2010Sabah S |
Pharmacology Research & Perspectives | 2022 |
|
Exploring pharmacological inhibition of Gq/11 as an analgesic strategy
Marwari S, Kowalski C, Martemyanov KA |
British Journal of Pharmacology | 2022 |
|
In vivo and in vitro characterization of GL0034, a novel long‐acting glucagon‐like peptide‐1 receptor agonist
Jones B, Burade V, Akalestou E, Manchanda Y, Ramchunder Z, Carrat G, Nguyen\u2010Tu M, Marchetti P, Piemonti L, Leclerc I, Thennati R, Vilsboll T, Thorens B, Tomas A, Rutter GA |
Diabetes, obesity & metabolism | 2022 |
|
Liraglutide increases islet Ca2+ oscillation frequency and insulin secretion by activating hyperpolarization-activated cyclic nucleotide-gated channels
Zaborska KE, Jordan KL, Thorson AS, Dadi PK, Schaub CM, Nakhe AY, Dickerson MT, Lynch JC, Weiss AJ, Dobson JR, Jacobson DA |
Diabetes, obesity & metabolism | 2022 |
|
The Interplay of Glucagon-Like Peptide-1 Receptor Trafficking and Signalling in Pancreatic Beta Cells
A Marzook, A Tomas, B Jones |
Frontiers in Endocrinology | 2021 |
|
Mechanisms of Beta-Cell Apoptosis in Type 2 Diabetes-Prone Situations and Potential Protection by GLP-1-Based Therapies
S Costes, G Bertrand, MA Ravier |
International journal of molecular sciences | 2021 |
|
The therapeutic potential of GLP‐1 receptor biased agonism
B Jones |
British Journal of Pharmacology | 2021 |
|
β-Cell Knockout of SENP1 Reduces Responses to Incretins and Worsens Oral Glucose Tolerance in High-Fat Diet–Fed Mice
H Lin, N Smith, AF Spigelman, K Suzuki, M Ferdaoussi, TA Alghamdi, SL Lewandowski, Y Jin, A Bautista, YW Wang, JE Fox, MJ Merrins, J Buteau, PE MacDonald |
Diabetes | 2021 |
|
Detour Ahead: Incretin Hormone Signaling Alters Its Intracellular Path as β-Cell Failure Progresses During Diabetes
MA Hussain, E Laimon-Thomson, SM Mustafa, A Deck, B Song |
Frontiers in Endocrinology | 2021 |
|
TCF7 is not essential for glucose homeostasis in mice
KD Kaur, CK Wong, LL Baggio, JL Beaudry, S Fuchs, BL Panaro, D Matthews, X Cao, DJ Drucker |
Molecular Metabolism | 2021 |
|
Partial agonism improves the anti-hyperglycaemic efficacy of an oxyntomodulin-derived GLP-1R/GCGR co-agonist
P Pickford, M Lucey, RM Rujan, ER McGlone, S Bitsi, FB Ashford, IR Corrêa, DJ Hodson, A Tomas, G Deganutti, CA Reynolds, BM Owen, TM Tan, J Minnion, B Jones, SR Bloom |
Molecular Metabolism | 2021 |
|
Structure based analysis of KATP channel with a DEND syndrome mutation in murine skeletal muscle
S Horita, T Ono, S Gonzalez-Resines, Y Ono, M Yamachi, S Zhao, C Domene, Y Maejima, K Shimomura |
Scientific Reports | 2021 |
|
Neuromedin U uses Gαi2 and Gαo to suppress glucose-stimulated Ca2+ signaling and insulin secretion in pancreatic β cells
W Zhang, H Sakoda, Y Nakazato, N Islam, F Pattou, J Kerr-Conte, M Nakazato, C Fürnsinn |
PloS one | 2021 |
|
Lipidated peptides derived from intracellular loops 2 and 3 of the urotensin II receptor act as biased allosteric ligands
Nassour H, Hoang TA, Martin RD, Dallagnol JC, Billard É, Létourneau M, Novellino E, Carotenuto A, Allen BG, Tanny JC, Fournier A, Hébert TE, Chatenet D |
The Journal of biological chemistry | 2021 |
|
Preferential Gq signaling in diabetes: an electrical switch in incretin action and in diabetes progression?
Colin G. Nichols, Nathaniel W. York, Maria S. Remedi |
Journal of Clinical Investigation | 2020 |
|
Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation
BA McLean, CK Wong, JE Campbell, DJ Hodson, S Trapp, DJ Drucker |
Endocrine reviews | 2020 |
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)